Impurity profiling of pharmaceuticals by thin-layer chromatography

Journal of Chromatography A

Volumn 1218, Issue 19, 2011, Pages 2722-2731

  Ferenczi Fodor, K ^a   Vegh Z ^a   Renger, B ^b  

^a GEDEON RICHTER LTD   (Hungary)

^b Vetter Pharma Fertigung GmbH and Co KG   (Germany)

Author keywords

Impurity profile; OPLC; Pharmaceuticals; Steroids

Indexed keywords

ACTIVE INGREDIENTS; ANALYTICAL METHOD; IMPURITY PROFILE; IMPURITY PROFILING; IN-PROCESS; OPLC; PHARMACEUTICAL ANALYSIS; PHARMACEUTICAL INDUSTRY; PHARMACEUTICAL RESEARCH AND DEVELOPMENT; PHARMACEUTICALS; STEROIDS;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPIDS; THIN LAYER CHROMATOGRAPHY;

DRUG PRODUCTS;

19 NORSTEROID; ALLYLESTRENOL; CHLORPROMAZINE; CIPROFLOXACIN; CLOPAMIDE; CLOPIDOGREL; DOXEPIN; DRUG; ETHINYLESTRADIOL; EZETIMIBE; FLUINDOSTATIN; GESTODENE; LEVONORGESTREL; MIRTAZAPINE; NANDROLONE; NANDROLONE DECANOATE; NORETHISTERONE; NORGESTREL; OMEPRAZOLE; PANTOPRAZOLE; PIROXICAM; PROMAZINE; RAMIPRIL; ROFECOXIB; TELMISARTAN; TRIFLUOPERAZINE;

ARTICLE; CHIRALITY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG IMPURITY; DRUG RESEARCH; DRUG SYNTHESIS; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; MASS SPECTROMETRY; OVERPRESSURED LAYER CHROMATOGRAPHY; PLANAR CHROMATOGRAPHY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE; THIN LAYER CHROMATOGRAPHY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DRUG CONTAMINATION; PHARMACEUTICAL PREPARATIONS;

EID: 79954630133     PISSN: 00219673     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chroma.2010.12.044     Document Type: Article

References (73)

1. Identification and Determination of Impurities in Drugs 2000, Elsevier. S. Görög (Ed.).
2. Bartos D., Görög S. Curr. Pharm. Anal. 2008, 4:215.
3. Görög S. Trends Anal. Chem. 2006, 25:755.
4. ICH guideline Q3A (R2), Impurities Testing Guideline: Impurities in New Drug Substances, CPMP/ICH/2737/99, http://ich.org/LoB/media/MEDIA422.pdf.
5. ICH guideline Q3B, Impurities in New Drug Products, CPMP/ICH/2738/99, http://ich.org/LoB/media/MEDIA421.pdf.
6. Guideline on the Limits of Genotoxic Impurities, EMEA/CHMP/QWP/251344/2006, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/wc500002903.pdf.
7. European Pharmacopeia, 7th ed., Council of Europe, Strasbourg, 2010; a, p. 2663; b, p.2551; c, p. 1356; d, p. 2692; e, p. 3052; f, p. 3251; g, p. 1731; h, p. 1814; i, p. 3095.
8. United States Pharmacopea, 32nd rev. U.S. Pharmacopeial Convention, Rockville, MD20852; a, p. 162; b, p. 3773. 2009.
9. Sherma J. Pharmacopoeial Forum 2001, 27:3420.
10. G. Morlock, W. Schwack, J. Chromatogr. A, 2010, doi:10.1016/j.chroma.2010.04.058.
11. Sherma J. J. AOAC Int. 2008, 91:51A.
12. Sherma J. J. AOAC Int. 2010, 93:754.
13. Krzek J., Sherma J. J. AOAC Int. 2010, 93:751.
14. Ferenczi-Fodor K., Végh Z. Identification and Determination of Impurities in Drugs 2000, Elsevier, Amsterdam, p. 146. S. Görög (Ed.).
15. Ferenczi-Fodor K., Végh Z., Renger B. Planar Chromatography. A Retrospective View for the Third Millennium 2001, 587. Springer, Budapest. S. Nyiredy (Ed.).
16. Nyiredy Sz., Végh Z., Ferenczi-Fodor K., Szepesi G. Handbook of Thin Layer Chromatography 2003, Marcel Dekker, New York, p. 807. 3rd ed. J. Sherma, B. Fried (Eds.).
17. Ferenczi-Fodor K., Végh Z., Renger B. Trends Anal. Chem. 2006, 25:778.
18. J. Kozma, Personal communication, 2008.
19. Szabó A., Kónya A., Winkler I., Máté Gy., Erdélyi B. J. Planar Chromatogr. 2006, 19:418.
20. Gulla V., Banerjee T., Patil S. Chromatographia 2008, 68:663.
21. Tamburini E., Bernardi T., Bianchini E., Pedrini P. J. Planar Chromatogr. 2009, 22:9.
22. Bernardi T., Tamburini E. J. Planar Chromatogr. 2009, 22:321.
23. Tyihák E., Mincsovics E., Kalász H. J. Chromatogr. 1979, 174:75.
24. Mincsovics E., Tyihák E., Kalász H. J. Chromatogr. 1980, 191:293.
25. Mincsovics E., Garami M., Kecskés L., Tapa B., Végh Z., Kátay Gy., Tyihák E. J. AOAC Int. 1999, 82:587.
26. Burger K. Fres. Z. Anal. Chem. 1984, 318:228.
27. Burger K., Köhler J., Jork H. J. Planar Chromatogr. 1990, 3:504.
28. Görög S. Anal. Bioanal. Chem. 2003, 377:852.
29. Bagócsi B., Fábián D., Laukó A., Mezei M., Mahó S., Végh Z., Ferenczi-Fodor K. J. Planar Chromatogr. 2002, 15:252.
30. K. Varga, Personal communication, 2009.
31. The Japanese Pharmacopoeia 15th ed., Ministry of Health, Labour and Welfare, Tokyo, 2006, http://www.jpdb.nihs.go.jp/jp15e/.
32. Ferenczi-Fodor K., Mahó S., Pap-Sziklay S., Török I., Borka L. Pharmeuropa 1997, 9:736.
33. Bagócsi B., Rippel G., Mezei M., Végh Z., Ferenczi-Fodor K. J. Planar Chromatogr. 2003, 16:359.
34. Wiszkidenszky A., Mahó S., Végh Z., Ferenczi-Fodor K. J. Planar Chromatogr. 1998, 11:463.
35. Kassai A., Szécsi A., Koppány A., Végh Z., Ferenczi-Fodor K. J. Planar Chromatogr. 2000, 13:30.
36. B. Bagócsi, Ph.D. Thesis, L. Eötvös University, Budapest, 2007.
37. Katona Z., Vincze L., Végh Z., Trompler Á., Ferenczi-Fodor K. J. Pharm. Biomed. Anal. 2000, 22:349.
38. Hiegel K., Spangenberg B. J. Chromatogr. A 2009, 1216:5052.
39. Maślanka A., Krzek J. J. Planar Chromatogr. 2007, 20:463.
40. Reddy T.S., Devi P.S. J. Liq. Chromatogr. Relat. Technol. 2008, 31:1204.
41. Antić D., Filipić S., Agbaba D. Acta Chromatogr. 2007, 18:199.
42. Agbaba D., Novovic D., Karljiković-Rajić K., Marinković V. J. Planar Chromatogr. 2004, 17:169.
43. Krzek J., Hubicka U., Szczepańczyk J. J. AOAC Int. 2005, 88:1530.
44. Hubicka U., Krzek J., Stankiewicz M. Curr. Pharm. Anal. 2009, 5:408.
45. ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A (R2), Geneva, 2003, (Parent Guideline dated 30 March 1995). http://www.ich.org/LOB/media/Media419.pdf.
46. Starek M., Krzek J., Dechnik J. J. Anal. Chem. 2009, 64:623.
47. Starek M., Krzek J., Tarsa M.M., Zylewski M. Chromatographia 2009, 69:351.
48. Mahadik M.V., Dhaneshwar S.R. Asian J. Pharm. Sci. 2007, 2:182.
49. Bhusari V.K., Mahadik M.V., Dhaneshwar S.R. Acta Chromatogr. 2009, 21:299.
50. Potale L.V., Damle M.C., Khodke A.S., Bothara K.G. Int. J. Pharm. Sci. Rev. Res. 2010, 2:35.
51. K. Varga, Personal communication, 2010.
52. ICH guideline Q1B, Photostability Testing of New Active Substances and Medicinal Products (CPMP/ICH/279/95), http://ich.org/LoB/media/MEDIA412.pdf.
53. Mielcarek J., Grobelny P., Osmałek T. J. Planar Chromatogr. 2009, 22:137.
54. Patel A.J., Desai S.S., Gabhe S.Y. Int. J. Pharm. Res. 2009, 1:66.
55. Jautz U., Morlock G. J. Chromatogr. A 2006, 1128:244.
56. Morlock G., Schwack W. LC-GC Europe 2008, 21:366.
57. Spectroscopy 24 (2009) 35.
58. CAMAGflash March, 2009.
59. Fuchs B., Süß R., Nimptsh A., Schiller J. Chromatogr. Suppl. 2009, 69:S95.
60. Crecelius A., Clench M.R., Richards D.S. Curr. Trends Mass Spectrom. 2004, 19(5S):28.
61. Crecelius A., Clench M.R., Richards D.S., Parr V. J. Pharm. Biomed. Anal. 2004, 35:31.
62. Thin Layer Chromatography in Chiral Separation and Analysis 2007, CRC/Taylor & Francis, Boca Raton, London, New York. T. Kowalska, J. Sherma (Eds.).
63. Bhushan R., Agarwal C. J. Planar Chromatogr. 2010, 23:7.
64. Salama N.N.E.-D.A. J. Planar Chromatogr. 2008, 21:441.
65. Sajewicz M., Gontarska M., Kronenbach D., Kowalska T. J. Planar Chromatogr. 2008, 21:349.
66. Glavnik V., Simonovska B., Vovk I. J. Chromatogr. A 2009, 1216:4485.
67. Dabrowska M., Krzek K. J. AOAC Int. 2010, 93:771.
68. Lepri L., Cincinelli A., Del Babba M. Thin Layer Chromatography in Chiral Separation and Analysis 2007, CRC/Taylor & Francis, Boca Raton, London, New York, P. 66. T. Kowalska, J. Sherma (Eds.).
69. Kochana J., Wilamowski J., Parczewski A. Chromatographia 2004, 60:481.
70. Kochana J., Parczewski A., Wilamowski J. J. Liq. Chromatogr. Relat. Technol. 2006, 29:1247.
71. The Global Pharma Health Fund (GPHF), http://www.gphf.org/web/en/start/index.htm.
72. G. Witman, M. Moskovitz, Dynamic Adsorbents Inc., Technical Info., http://www.dynamicadsorbents.com/tlccounterfeit.htm.
73. Mukhopadhay R. Anal. Chem. 2007, 79:2623.